Skip to content
Open access

Pretreatment TyG-BMI predicts CD19 CAR-T persistence and prognosis in diffuse large B-cell lymphoma

Aug 2026 · Frontiers in Oncology · Vol 16 · 0 citations · 57 references
Medicine

TL;DR

TyG-BMI is an independent prognostic factor in DLBCL that refines IPI-based stratification, and elevated pre-infusion TyG-BMI is associated with attenuated CAR-T cell persistence and inferior outcomes.

Abstract

Background Although CD19 CAR-T cell therapy has improved outcomes in relapsed or refractory diffuse large B-cell lymphoma (DLBCL), responses are variable and predictive biomarkers are lacking. The triglyceride glucose-body mass index (TyG-BMI)—a surrogate of insulin resistance—has shown prognostic value in solid tumors, but its relevance to DLBCL and CAR-T efficacy remains unknown. Methods We retrospectively analyzed 204 newly diagnosed DLBCL patients treated with rituximab-containing regimens, stratified by median TyG-BMI. Prognostic associations were assessed by Kaplan-Meier and multivariate Cox regression, and a nomogram was constructed. In an exploratory sub-analysis, 20 patients who received CD19 CAR-T therapy were assessed. CAR-T cell persistence was measured by flow cytometry one week post-infusion and correlated with pre-infusion TyG-BMI by Pearson analysis. CRS and ICANS were graded per ASTCT criteria. Post-CAR-T survival was compared by Kaplan-Meier analysis stratified by median pre-infusion TyG-BMI. Results High TyG-BMI was independently associated with poorer PFS (HR, 2.146; 95% CI, 1.092–4.214; P = 0.027) and OS (HR, 2.531; 95% CI, 1.084–5.913; P = 0.032), and further stratified risk within IPI risk groups and across disease stages. A nomogram incorporating TyG-BMI, IPI, and bone marrow involvement predicted 1-, 3-, and 5-year OS (AUC: 0.886, 0.799, 0.772). In the CAR-T subcohort (n = 20), elevated pre-infusion TyG-BMI was significantly inversely correlated with CAR-T cell persistence at one week post-infusion (r = -0.570, P = 0.009). Patients with high pre-infusion TyG-BMI experienced inferior responses to CAR-T therapy, with shorter median PFS (5.0 vs. 19.5 months) and OS (39.0 vs. 81.0 months) compared with the low TyG-BMI group. Conclusion TyG-BMI is an independent prognostic factor in DLBCL that refines IPI-based stratification, and elevated pre-infusion TyG-BMI is associated with attenuated CAR-T cell persistence and inferior outcomes. This readily available metabolic index may aid risk assessment and treatment planning in DLBCL.

Read PDF

Similar papers

Open access Aug 2026

InflaMix Predicts Severe CRS, ICU Admission, and Progression‐Free Survival After CAR‐T Therapy in LBCL

The prognostic performance of the recently developed INFLAmmation MIXture Model (InflaMix) in an independent bicentric cohort of patients with large B‐cell lymphoma receiving commercial CAR‐T cells is evaluated, focusing on treatment‐related toxicities.

Eugenio Galli, D. Mannina, Alessandro Corrente et al. · 1 citation
Open access Aug 2026

Impact of IL-6 and ferritin dynamics on clinical outcomes after anti-CD19 CAR-T cell therapy in diffuse large B-cell lymphoma patients

Background Interleukin-6 (IL-6) and ferritin are routinely monitored during chimeric antigen receptor T-cell (CAR-T) therapy; however, their temporal dynamics and outcome-specific relevance remain inadequately characterized. This study aimed to evaluate the value of IL-6 and ferritin at multiple time points in patients...

Ling Gao, Yan-Yan Mao, Cai Sun et al. · 0 citations
Oct 2026

CAR T-cell therapy for relapsed and refractory B-cell non-Hodgkin lymphoma: a single-centre 5-year real-world experience study at Ghent University Hospital.

BACKGROUND Relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) remains challenging to treat, particularly in patients ineligible for high-dose chemotherapy and autologous stem cell transplantation. Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising treatment. AIMS We describe the e...

Julie Vandewiele, Chiel Gharakhani, C. De Vriendt et al. · 0 citations
Open access Sep 2026

Association between CAR T-cell persistence and improved response to salvage radiotherapy in patients with DLBCL

Background and purpose While Chimeric antigen receptor (CAR) T-cell therapy has transformed treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL), over half of patients relapse within 1 year with poor prognosis. Salvage radiotherapy (sRT) achieves high local response rates, but which subgroups benefit...

Jia-Qi Fan, N. Kutsch, J. Heger et al. · 0 citations
Open access Sep 2026

Dynamic risk stratification using early CAR-T expansion in R/R LBCL treated with axicabtagene ciloleucel.

The clinical utility of routine monitoring of chimeric antigen receptor (CAR) T-cell expansion post-infusion remains controversial. We conducted a retrospective analysis of a prospectively collected cohort of 176 patients with relapsed/refractory large B-cell lymphoma (LBCL) treated with axicabtagene ciloleucel (axi-ce...

Brydon Panozzo, S. Robinson, A. Minson et al. · 0 citations
Open access Sep 2026

Composite clinical scores in real-world extensive-stage small-cell lung cancer patients treated with chemo-immunotherapy.

BACKGROUND Composite scores such as Lung Immune Prognostic Index (LIPI), modified Glasgow Prognostic Score (mGPS), EPSILoN, Pan Immune-Inflammation Value (PIV) and Systemic Immune-Inflammation Index (SII) have shown prognostic value in solid tumors, but evidence in extensive-stage small-cell lung cancer (ES-SCLC) are l...

Teresa Beninato, Giulia Stasi, G. Montelatici et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.